Who are Intra ovarian by platelet rich plasma's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PRFM treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intra-ovarian-by-platelet-rich-plasma.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Intra ovarian by platelet rich plasma — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra ovarian by platelet rich plasma (Intra ovarian by platelet rich plasma) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative medicine / Autologous cell therapy. Area: Reproductive Medicine / Fertility.

phase 3 Regenerative medicine / Autologous cell therapy Reproductive Medicine / Fertility Biologic Live · refreshed every 30 min

Target snapshot

Intra ovarian by platelet rich plasma (Intra ovarian by platelet rich plasma) — Beni-Suef University. Platelet-rich plasma (PRP) injected intra-ovarian delivers growth factors and cytokines to stimulate ovarian function and improve fertility outcomes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intra ovarian by platelet rich plasma TARGET	Intra ovarian by platelet rich plasma	Beni-Suef University	phase 3	Regenerative medicine / Autologous cell therapy
PRFM treatment	PRFM treatment	The New York Eye & Ear Infirmary	phase 3	Regenerative medicine / Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative medicine / Autologous cell therapy class)

Beni-Suef University · 1 drug in this class
The New York Eye & Ear Infirmary · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intra ovarian by platelet rich plasma — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-ovarian-by-platelet-rich-plasma. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab